ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1027

Factors Associated With Decisions To Adjust Therapy For Rheumatoid Arthritis Patients In Moderate To High Disease Activity

Yomei Shaw1, Chung-Chou H. Chang2,3, Heather Eng4, Ilinca D. Metes5, Stephen R. Wisniewski6, Mark S. Roberts1 and Marc C. Levesque7, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, 3Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 4Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 5Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Data analysis, registries, rheumatoid arthritis (RA) and therapeutic targeting

  • Tweet
  • Email
  • Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: The American College of Rheumatology (ACR) recommends treating rheumatoid arthritis (RA) to the target of low disease activity or remission with traditional and biologic disease-modifying anti-rheumatic drugs (DMARDs).  However, significant numbers of RA patients do not receive care consistent with these recommendations.  Previously, we found that age, race, physician age, current use of a biologic, Disease Activity Score-28 joint  (DAS28-CRP), and RA duration were significantly associated with decisions to adjust DMARD therapy for RA patients with moderate to high disease activity.  Here, we present an update to our findings with new covariates added to the analysis, including income and comorbidities, which were adjusted for to prevent confounding bias in the effects of age and race.

Methods: Data was drawn from the University of Pittsburgh Rheumatoid Arthritis Comparative Effectiveness Research (RACER) observational registry (2010-13) on visits where patients had moderate to high disease activity for at least 3 months. Therapy adjustment was defined as adding, switching, or increasing the dose of oral or biologic DMARD therapy. To assess this binary outcome, a generalized linear model with logit link was used. Generalized estimating equations (GEE) with clustering by patient were used to account for correlation between different visits for each patient. Variables significant in univariable GEE analyses (Wald test on coefficient has p<0.2) were entered into a multivariable model, then backwards selection was used to choose the final model by removing variables with p>0.05. The model controlled for patient demographic and disease characteristics: age, race, gender, RA duration, DAS28-CRP, Short Form 12 (SF12) physical and mental components, Health Assessment Questionnaire (mdHAQ), and two new variables (income and Charlson comorbidity index).

Results: There were 562 visits for 255 patients with moderate to high disease activity for at least 3 months. Therapy was adjusted at 23.1% of visits. The odds ratios (OR; [95% CI]) of adjusting therapy were decreased by longer disease duration (0.965; [0.943,0.987]), physician age (0.955; [0.932,0.978]), current use of biologic therapy (0.394; [0.240,0.648]), and lower DAS28-CRP (0.640;  [0.455,0.900]).  Age and race were no longer significant.

Conclusion: In the RACER observational cohort, 76.9% of RA patients with moderate/high disease activity for at least 3 months did not have DMARD therapy adjusted.  Physician age, duration of RA, lower DAS28, and current use of biologic therapy decreased the likelihood of therapy adjustment. The fact that age and race were no longer significant upon the addition of Charlson comorbidity index and income to the model suggests that these new variables may partially explain the previously observed effects of age and race. These results can be used to improve treat-to-target strategies in clinical practice. Our future research will explore how other factors such as prior use of DMARDs/corticosteroids, insurance coverage, and risk aversion may influence treatment decisions for RA patients with moderate/high disease activity.


Disclosure:

Y. Shaw,

Genentech and Biogen IDEC Inc.,

2;

C. C. H. Chang,
None;

H. Eng,

Genentech and Biogen IDEC Inc.,

2;

I. D. Metes,

Genentech and Biogen IDEC Inc.,

2;

S. R. Wisniewski,

Genentech and Biogen IDEC Inc.,

2;

M. S. Roberts,
None;

M. C. Levesque,

Genentech and Biogen IDEC Inc.,

2,

UCB,

5,

AbbVie,

9,

Crescendo,

5,

Baxter Healthcare,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-decisions-to-adjust-therapy-for-rheumatoid-arthritis-patients-in-moderate-to-high-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology